HIV/AIDS News and Research

RSS

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

COVID-19 vaccine breakthrough infections among immunocompromised individuals

A study of breakthrough infections in immunocompromised people following two doses of the Pfizer/BioNTech vaccine against SARS-CoV-2 concluded that immunocompromised people would be best served with a third dose of the vaccine for better protection.

19 Oct 2021

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.

30 Sep 2021

Columbia University and partners launch and operate New York City's first Pandemic Response Institute

Through a groundbreaking new award from New York City Economic Development Corporation (NYCEDC), Columbia University – through its Mailman School of Public Health – and a consortium of academic, community, government, and corporate partners will launch and operate New York City's first Pandemic Response Institute (PRI).

29 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

I got a ‘mild’ breakthrough case. Here’s what I wish I’d known.

The test results that hot day in early August shouldn’t have surprised me — all the symptoms were there. A few days earlier, fatigue had enveloped me like a weighted blanket. I chalked it up to my weekend of travel. Next, a headache clamped down on the back of my skull.

20 Sep 2021

New QCovid tool helps identify vaccinated groups at highest risk of Covid-19 hospitalization and death

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalization or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

20 Sep 2021

Experts show waning effectiveness of COVID-19 vaccines over time

In a letter to The New England Journal of Medicine, publishing online September 1, 2021, an interdisciplinary team of physicians and public health experts at University of California San Diego measured the effectiveness of COVID-19 mRNA vaccines among health workers at UC San Diego Health, most notably during the emergence of the highly transmissible delta virus variant and coincident with the end of the state's mask mandate, allowing fully vaccinated persons to forgo face coverings in most places.

1 Sep 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

New $14.5 million NIH grant to support research on HIV treatment and care in Central Africa

Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations.

24 Aug 2021

CUNY SPH and NYC Health Department receive grant to study long-acting injectables for HIV

The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a thirty month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").

23 Aug 2021

HRC Foundation and Us Helping Us launch first national in-home HIV testing program in the U.S.

Today, The Human Rights Campaign Foundation, the educational arm of the nation’s largest lesbian, gay, bisexual, transgender and queer civil rights organization, in partnership with Us Helping Us, launched the United States’ first national in-home HIV testing program centered around reaching communities disproportionately impacted by HIV—Black and Latinx gay, bisexual men and transgender women of color.

23 Aug 2021

Epidemiology study provides clues for designing new strategies to curb HIV-related mortality in China

In China, HIV-related deaths are on the rise, despite years of efforts by the government to control them. In an effort to overcome this, a new study published in Chinese Medical Journal dug deep into HIV-related data of nearly 30 years.

19 Aug 2021

CUNY SPH and NYC Health Department receive $3.3 million grant to test new HIV intervention

The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.

18 Aug 2021

Global death toll from suicide has increased by 20,000 over the past 30 years, analysis finds

The overall global death toll from suicide has risen by nearly 20,000 over the past 30 years, despite a significant fall in age-specific suicide rates during this period, finds an analysis of international data, published online in the journal Injury Prevention.

17 Aug 2021

NIH scientists develop new sample preparation method to detect SARS-CoV-2

Scientists at the National Institutes of Health (NIH) have developed a new sample preparation method to detect SARS-Cov-2, the virus that causes COVID-19.

16 Aug 2021

Scientists urge increased attention to persistent COVID-19 infections in immunocompromised people

In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.

5 Aug 2021

Study explores why COVID-19 lockdown does not work in Africa as first pandemic response

In an African pandemic it is more productive to consider lockdowns, after using other non-medical measures first, Especially in countries with high levels of poverty and corruption, says Prof Nicholas Ngepah, a Professor of Economics at the University of Johannesburg in South Africa.

28 Jul 2021

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Upon first inspection, the mutations in the highly contagious delta covid variant don't look that worrisome.

28 Jul 2021

Report highlights global shortfalls to end HIV infections among children and young women

In the final report from the Start Free, Stay Free, AIDS Free initiative, UNAIDS and partners warn that progress towards ending AIDS among children, adolescents and young women has stalled and none of the targets for 2020 were met.

23 Jul 2021

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.

15 Jul 2021